Medium-term Effects of Treatments in Autoimmune Encephalitis
Key facts
- Who runs it
- Hospices Civils de Lyon
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 1 Sept 2024
- Expected to end
- 1 Mar 2027
- Type of study
- Observational, 6 groups
- Treatments tested
- We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).
- Record updated
- 20 August 2025
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Adult or child patient with encephalitis defined as anti-GAD, NMDAR, LGI1, CASPR2, IgLON5 or GFAP
- Untreated or with a decision to treat within the previous 30 days
Who cannot take part
- Refusal by the referring doctor to participate or refusal by the patient mentioned in the objection to the use of his/her clinical data
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Autoimmune encephalitides are severe neurological disorders requiring urgent treatment, even though there is no standard guideline by lack of empirical evidence. Commonly used treatments are divided into so-called first-line (steroids, intravenous immunoglobulins, plasma exchanges) and second-line (rituximab, cyclophosphamide, tocilizumab, others), and may be used in association or sequentially. There is no standard practice, and initial treatment protocol may consist in first-line alone, first-line with rituximab, or first-line with dual immunosuppression (rituximab and cyclophosphamide). Absence of clear response to initial treatment in the first 4 to 6 weeks may indicate undertreatment and is generally followed by treatment escalation, mostly to dual immunosuppression. However, as the frequency of non-responders to initial treatment is unknown, it is still unclear whether dual immunosuppression should be offered to all patients from inception.
The 6 groups in the trial
- group 1 : Patients with NMDAR encephalitis
Patients with untreated anti-NMDAR encephalitis or with a decision to treat within the previous 30 days
Treatment: We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).
- group 2 : Patients with GAD encephalitis
Patients with untreated anti-GAD encephalitis or with a decision to treat within the previous 30 days
Treatment: We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).
- group 3 : Patients with LGI1 encephalitis
Patients with untreated anti-LGI1 encephalitis or with a decision to treat within the previous 30 days
Treatment: We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).
- group 4 : Patients with IgLON5 encephalitis
Patients with untreated anti-IgLON5 encephalitis or with a decision to treat within the previous 30 days
Treatment: We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).
- group 5 : Patients with GFAP encephalitis
Patients with untreated anti-GFAP encephalitis or with a decision to treat within the previous 30 days
Treatment: We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).
- group 6 : Patients with CASPR2 encephalitis
Patients with untreated anti-CASPR2 encephalitis or with a decision to treat within the previous 30 days
Treatment: We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Medium-term Effects of Treatments in Autoimmune Encephalitis (META): a Real-life, Observational Prospective Study
- Record updated
- 20 August 2025